SEQUENTIAL USE OF MTOR-INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SAFETY AND EFFICACY FOLLOWING FAILURE OF RECEPTOR TYROSINE KINASE INHIBITOR (TKI) TREATMENT

被引：0
|
作者：
Busch, J. [1 ]
Kempkensteffen, C. [1 ]
Gruenwald, V [2 ]
Weinkauf, L. [1 ]
Hinz, S. [1 ]
Magheli, A. [1 ]
Miller, K. [1 ]
Johannsen, M. [1 ]
Weikert, S. [1 ]
机构：
[1] Charite, Dept Urol, D-13353 Berlin, Germany
[2] Hannover Med Sch, Clin Haematol Haemostaseol Oncol & Stem Cell Tran, Hannover, Germany
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2011年 / 10卷 / 02期
关键词：
D O I：
10.1016/S1569-9056(11)60713-6
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [31] Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)
    Santini, Daniele
    Santoni, Matteo
    Conti, Alessandro
    Procopio, Giuseppe
    Verzoni, Elena
    Galli, Luca
    di Lorenzo, Giuseppe
    De Giorgi, Ugo
    De Lisi, Delia
    Nicodemo, Maurizio
    Maruzzo, Marco
    Massari, Francesco
    Buti, Sebastiano
    Biasco, Elisa
    Ricotta, Riccardo
    Porta, Camillo
    Vincenzi, Bruno
    Marchetti, Paolo
    Cascinu, Stefano
    Tonini, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)
    Santini, D.
    Santoni, M.
    Conti, A.
    Procopio, G.
    Verzoni, E.
    Galli, L.
    Di Lorenzo, G.
    De Giorgi, U.
    De Lisi, D.
    Nicodemo, M.
    Maruzzo, M.
    Massari, F.
    Buti, S.
    Biasco, E.
    Ricotta, R.
    Porta, C.
    Vincenzi, B.
    Marchetti, P.
    Cascinu, S.
    Tonini, G.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S512 - S513
  • [33] Safety and efficacy of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC) who failed previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: A subanalysis of REACT
    Rha, Sun Young
    Lee, Se-Hoon
    Ou, Yen-Chuan
    Ahn, Jin-Hee
    Chang, Yen-Hwa
    Srimuninnimit, Vichien
    Lim, Ho Yeong
    Chung, Ik-Joo
    Pang, See-Tong
    Xue, Hong-Ling
    Panneerselvam, Ashok
    Chung, Jooseop
    Toh, Chee-Keong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Multicenter phase II clinical trial of everolimus in Japanese patients with unresectable or metastatic renal cell carcinoma (mRCC) after failure of treatment with first-line tyrosine kinase inhibitor (TKI) therapy
    Ozono, Seiichiro
    Oyama, Masafumi
    Nozawa, Masahiro
    Fujimoto, Kiyohide
    Kishida, Ken
    Tokuda, Noriaki
    Kimura, Go
    Nishimura, Kazuo
    Matsubara, Akio
    Matsuyama, Hideyasu
    Sugiyama, Takayuki
    Kamba, Tomomi
    Kume, Haruki
    Masumori, Naoya
    Oya, Mototsugu
    Kanayama, Hiro-Omi
    Naito, Seiji
    Hinotsu, Shiro
    Shimozuma, Kojiro
    Akaza, Hideyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [35] What is the benfit of mTOR inhibitors (mTORi) rechallenge in metastatic renal clear cell carcinoma (mRCC) patients (pts) initially treated with TKI?
    Maj-Hes, Agnes
    Elaidi, Reza-Thierry
    Medioni, Jacques
    Scotte, Florian
    Kramer, Gero
    Hoeltl, Wolfgang
    Gachet, Julie
    Teghom, Corine
    Gornadha, Yohan
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [36] Tyrosine-kinase inhibitor sorafenib (S) in treatment of metastatic renal cell carcinoma cancer (mRCC) with lung metastases
    Popova, Irina L.
    Vladimirova, Liubov Yu
    Abramova, Natalya A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features
    Jae-Lyun Lee
    Inkeun Park
    Kwonoh Park
    Seongjoon Park
    Yongcheol Ahn
    Jin-Hee Ahn
    Tae-Won Kim
    Shin Ahn
    Cheryn Song
    Jun Hyuk Hong
    Choung-Soo Kim
    Hanjong Ahn
    Journal of Cancer Research and Clinical Oncology, 2012, 138 : 687 - 693
  • [38] Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Park, Seongjoon
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Kim, Tae-Won
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (04) : 687 - 693
  • [39] Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC)
    Urun, Yuksel
    Gray, Kathryn P.
    Signoretti, Sabina
    McDermott, David F.
    Atkins, Michael B.
    Lampron, Megan E.
    Freedman, Matthew
    Choueiri, Toni K.
    Pomerantz, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Efficacy and safety of approved first-line tyrosine kinase inhibitor (TKI) treatment in patients with metastatic renal cell carcinoma (mRCC): A network meta-analysis based on phase II/III randomised clinical trials (RCTs).
    Manz, Kirsi
    Fenchel, Klaus
    Eilers, Andreas
    Morgan, Jon
    Wittling, Kirsten
    Dempke, Wolfram C. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345